RSS   Newsletter   Contact   Advertise with us
Post Online Media

HTG Molecular Diagnostics appoints Ann F. Hanham as chair

HTG Molecular DiagnosticsHTG Molecular Diagnostics, a provider of instruments and reagents for NGS-based molecular profiling applications, announced that Ann F. Hanham has been appointed to the chair of the company's board of directors.
Dr. Hanham, a director since August 2016, has served for more than 15 years in the life science investment industry as a founding member and managing partner of BAR Capital Management, LLC, and, prior to that, as a managing director and general partner of Burrill & Company.

Earlier in her career, Dr. Hanham held positions of increasing responsibility in clinical and regulatory affairs and product development at various companies including InterMune, Otsuka America Pharmaceuticals, Celtrix Pharmaceuticals, and Becton Dickinson and Company.

Dr. Hanham currently serves as a director for two other public companies, and has served on the boards of directors of over 20 companies, both private and public, throughout her distinguished career.




We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy